Nrx pharmaceuticals announces strategic change in development of nrx-100 (iv ketamine) at dawson james small cap investor conference

Previously announced data sharing agreement for intravenous ketamine newly available data highlight the need for a labeled form of iv ketamine that can qualify for insurance reimbursement need for intravenous ketamine is heightened by recent failure of intranasal ketamine to treat suicidality. currently approved esketamine is not available for patients with bipolar depression the importance of appropriately labeled intravenous ketamine is highlighted by recent fda warning letter and prior warning letters against compounding and off-label uses of ketamine for psychiatric care jupiter, fla.
NRXP Ratings Summary
NRXP Quant Ranking